166 related articles for article (PubMed ID: 22443228)
1. Current status of targeted therapies in advanced gastric cancer.
De Vita F; Giuliani F; Silvestris N; Rossetti S; Pizzolorusso A; Santabarbara G; Galizia G; Colucci G; Ciardiello F; Orditura M
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S29-34. PubMed ID: 22443228
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
3. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for gastric cancer.
Asaoka Y; Ikenoue T; Koike K
Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
[TBL] [Abstract][Full Text] [Related]
7. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
[TBL] [Abstract][Full Text] [Related]
9. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
11. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
13. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
15. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
17. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
18. [Molecular targeting agents for advanced or recurrent gastric cancer patients].
Fuse N
Nihon Rinsho; 2012 Oct; 70(10):1819-26. PubMed ID: 23198568
[TBL] [Abstract][Full Text] [Related]
19. Novel investigational drugs for gastric cancer.
Vecchione L; Orditura M; Ciardiello F; De Vita F
Expert Opin Investig Drugs; 2009 Jul; 18(7):945-55. PubMed ID: 19466878
[TBL] [Abstract][Full Text] [Related]
20. Emerging tyrosine kinase inhibitors for esophageal cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2013 Jun; 18(2):219-30. PubMed ID: 23725567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]